Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1. To evaluate and compare PFS per RECIST 1.1 as assessed by BICR in subjects. treated with pembrolizumab plus axitinib versus sunitinib monotherapy. 2. To evaluate and compare OS in subjects treated with pembrolizumab plus axitinib versus sunitinib monotherapy.
Critère d'inclusion
- advanced kidney cancer